Nabriva Therape Ads (NBRV), shares price dropped -15% to $2.89 in the after-market sessionas a biopharmaceutical company specializing in the development andcommercialization of new antibiotics for treatment of serious infections,announced the pricing of its public offering of 6,000,000 ordinary shares at a price of $2.50 per share (or pre-funded warrant).
In connection with this offering, H.C. Wainwright & Co. serves as the exclusive placement agent. Northland Securities, Inc. provides the financial advisory services. Before the placement agent’s fees and other estimated offering expenses payable by Nabriva Therapeutics, the gross proceeds from the offering are $15 million.
Providing customary closing conditions are satisfied, the offering is expected to close by December 15, 2020.